Publicacions actualitzades

Grimoire_spell_book_by_moxylyn

 

Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, Munteis E, Mansilla MJ, Presas-Rodriguez S, Navarro-Barriuso J, Ramo-Tello C, Martínez-Cáceres EM.Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.CNS Neurosci Ther. 2018 Apr 15. doi: 10.1111/cns.12851. [Epub ahead of print]

Teniente-Serra A, Ramo-Tello C, Martinez-Caceres EM.Immunomonitoring Lymphocyte Subpopulations in Multiple Sclerosis Patients.In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]. Brisbane (AU): Codon Publications; 2017 Nov 27. Chapter 9.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand’Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A.Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.Mult Scler. 2017 Oct 1:1352458517735191. doi: 10.1177/1352458517735191. [Epub ahead of print]

Lorscheider J, Jokubaitis VG, Spelman T, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, Trojano M, Duquette P, Girard M, Prat A, Grand’Maison F, Grammond P, Pucci E, Boz C, Sola P, Ferraro D, Spitaleri D, Lechner-Scott J, Terzi M, Van Pesch V, Iuliano G, Bergamaschi R, Ramo-Tello C, Granella F, Oreja-Guevara C, Butzkueven H, Kalincik T; MSBase Study Group.Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.Neurology. 2017 Sep 5;89(10):1050-1059. doi: 10.1212/WNL.0000000000004330. Epub 2017 Aug 9.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A, Cano-Orgaz A, Mansilla MJ, Quirant-Sánchez B, Navarro-Barriuso J, Fernández-Sanmartín MA, Presas-Rodríguez S, Ramo-Tello C, Martínez-Cáceres EM. Monitoring CD49d receptor occupancy: A method to optimize and personalize natalizumab therapy in multiple sclerosis patients.
Cytometry B Clin Cytom. 2017

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand’Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C,(…), Kalincik T; MSBase Study Group. Defining secondary progressive multiple sclerosis. Brain.139(Pt 9) 2395-405.2016

Mansilla MJ, Contreras-Cardone R, Navarro-Barriuso J, Cools N, Berneman Z, Ramo-Tello C, Martínez-Cáceres EM. Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. J Neuroinflammation. 2016 May 20;13(1):113.

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225.

Teniente-Serra A, Hervás JV, Quirant-Sánchez B, Mansilla MJ, Grau-López L, Ramo-Tello C, Martínez-Cáceres EM. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients. CNS Neurosci Ther. 2016 Apr 15.

Hervás-García JV, Montané E, Serrado-Iglesias A, Ramo-Tello C. Toxic hepatitis after concomitant interferon beta and aloe vera treatment in a patient with multiple sclerosis: A case report. Neurologia. 2016 Feb 10. pii: S0213-4853(16)00003-7. English, Spanish. No abstract available.

Teniente-Serra A, Grau-López L, Mansilla MJ, Fernández-Sanmartín M, Ester Condins A, Ramo-Tello C, Martínez-Cáceres E. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients. Autoimmunity. 2016 Jun;49(4):219-28.

Ramo-Tello C, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás JV, Grau-López L. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.Mult Scler. 2016 Jan;22(1):117-21

Presas-Rodríguez S, Grau-López L, Hervás-García JV, Massuet-Vilamajó A, Ramo-Tello C. Myelitis: Differences between multiple sclerosis and other aetiologies.Neurologia. 2016 Mar;31(2):71-75.

Hervás JV, Presas-Rodríguez S, Crespo-Cuevas AM, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Neurodegener Dis Manag. 2015 Oct;5(5):399-402.

Mansilla MJ, Sellès-Moreno C, Fàbregas-Puig S, Amoedo J, Navarro-Barriuso J, Teniente-Serra A, Grau-López L, Ramo-Tello C, Martínez-Cáceres EM.Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis.CNS Neurosci Ther. 2015 Mar;21(3):222-30.

Grau-López L, Teniente-Serra A, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás JV, Martínez-Cáceres EM, Ramo-Tello C. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses. Mult Scler. 2015 Apr; 21(5):646-50.

Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2014 May; 20(6):717-725.

Hervas-Garcia JV, Grau-Lopez L, Domenech-Puigcerver S, Ramo-Tello C. Encephalopathy and neuromyelitis optica: the importance of recognising atypicalsymptoms. Rev Neurol. 2014 Jan 1; 58(1):20-4. Click here to read it in spanish.Free Article

Presas-Rodriguez S, Hernandez-Perez M, Grau-Lopez L, Massuet-Vilamajo A,Ramo-Tello C. Lesion of the trigeminal nucleus caused by herpes simplex virus. Rev Neurol 2013 Dec 1; 57(11):526-527.Free Article

Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, Torres F, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2014 May;20(6):717 – 725.

Dra Ramo-Tello, C; Dra. Grau-López L. Corticoterapia oral en megadosis para el tratamiento del brote de esclerosis múltiple.  Revista Española de Esclerosis Múltiple 2013 Sep; 27:5-9.

Ramo-Tello C. Precaucions en l’ús dels fàrmacs per a l’esclerosi múltiple. Butlletí d’ Informació Farmacèutica(BIT).Nov.2012 Generalitat de Catalunya. Departament de Salut. ISSN: 0213-7801(format paper) /ISSN: 1579-9441 (format digital)

Grau-Lopez L, Granada ML, Raich D, Naranjo M, Borras FE, Martinez-Caceres EM, Ramo-Tello C et al. Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients. BMC Neurol 2012 Sep 24;12(1):103. Free PMC Article

Raich-Regue D, Naranjo-Gomez M, Grau-Lopez L, Ramo C, Pujol-Borrell R, Martinez-Caceres E, et al. Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy. Vaccine 2012 Jan 5;30(2):378-387.

Raich-Regue D, Grau-Lopez L, Naranjo-Gomez M, Ramo-Tello C, Pujol-Borrell R, Martinez-Caceres E, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012 Mar;42(3):771-782.

 Abraira V, Alvarez-Cermeno JC, Arroyo R, Camara C, Casanova B, Cubillo S, Ramo Tello C et al. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. J Immunol Methods 2011 Aug 31;371(1-2):170-173.

Arroyo E, Grau C, Ramo Tello C, Parra J, Sanchez-Solino O, GAP Study Group. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project. Eur Neurol 2011;65(2):59-67.

Blanco Y, Ercilla-Gonzalez G, Llufriu S, Casanova-Estruch B, Magraner MJ, Ramio-Torrenta L, Ramo Tello C et al. HLA-DRB1 typing in Caucasians patients with neuromyelitis optica. Rev Neurol 2011 Aug 1;53(3):146-152 .Free Article

Devonshire V, Lapierre Y, Macdonell R, Ramo Tello C, Patti F, Fontoura P, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011 Jan;18(1):69-77

Grau Lopez L, Ramo Tello C. Esclerosis Múltiple Pediátrica. 2011.

Grau-Lopez L, Raich D, Ramo Tello C, Naranjo-Gomez M, Davalos A, Pujol-Borrell R, et al. Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis. Eur J Neurol 2011 Aug;18(8):1101-1104

Grau-Lopez L, Sierra S, Martinez-Caceres E, Ramo Tello C. Analysis of the pain in multiple sclerosis patients. Neurologia 2011 May;26(4):208-213. Free Article

Naranjo-Gomez M, Raich-Regue D, Onate C, Grau-Lopez L, Ramo-Tello C, Pujol-Borrell R, et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med 2011 Jun 9;9:89. Free PMC Article

Arroyo E, Gonzalez M, Grau C, Arnal C, Bujanda M, Ramo Tello C ,de Castro P, et al. Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis. Neurologia 2010 Nov-Dec;25(9):544-551.

Arroyo E, Grau C, Ramo-Tello C, Parra J, Sanchez-Solino O, por el grupo espanol del estudio GAP. Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results. Neurologia 2010 Sep;25(7):435-442.

Espinosa G, Mendizabal A, Minguez S, Ramo-Tello C, Capellades J, Olive A, et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2010 Feb;39(4):246-256.

Grau Lopez L, Ramo-Tello C. Vértigo periférico y vértigo central. 2010 (ISBN:978-84-694-483.3)

Otero S, Batlle J, Bonaventura I, Brieva L, Bufill E, Cano A, Ramo Tello C et al. Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia. Rev Neurol 2010 May 16;50(10):623-633. Free Article

Grau-Lopez L, Raich D, Ramo Tello C, Naranjo-Gomez M, Davalos A, Pujol-Borrell R, et al. Myelin peptides in multiple sclerosis. Autoimmun Rev 2009 Jul;8(8):650-653.

Pauls E, Ballana E, Moncunill G, Bofill M, Clotet B, Ramo Tello C, et al. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS 2009 Jan 14;23(2):266-268.

Lopez LG, Ramo Tello C. Communication of the diagnosis of multiple sclerosis: the patient’s opinion. Neurologia 2008 Jul-Aug;23(6):367-372.

Grau Lopez L, Sedano Tous MJ, Ramo Tello C. Multiple sclerosis and herpes encephalitis. Med Clin (Barc) 2007 Sep 15;129(9):356. Article in spanish.

Illa Sendra I, Garcia De Yebenes Prous J, Ramo Tello C, Polo Esteban JM, Molinuevo Guix JL, Robles Bayon A, et al. Present and future of neurology in Spain. Neurologia 2001 Nov;16(9):408-417.

Ramo-Tello C, Leon-Colombo T. What treatment should be given for multiple sclerosis at the present time? Rev Neurol 2000 May 16-31;30(10):993-995.

 Fernandez Piqueras J, Santos J, Visedo G, Perez de Castro I, Puertollano R, Montejo J, Ramo-Tello C, et al. Familial cosegregation of manic-depressive illness and a form of hereditary cerebellar ataxia. Am J Med Genet 1995 Jun 19;60(3):206-207

Ramo Tello C, Gonzalez JL, Hernandez Gallego J, Calandre L, Bermejo F. Familial paroxysmal ataxia. Neurologia 1986 Sep-Oct;1(5):212-215.

Anuncis

Deixa un comentari

Fill in your details below or click an icon to log in:

WordPress.com Logo

Esteu comentant fent servir el compte WordPress.com. Log Out /  Canvia )

Google+ photo

Esteu comentant fent servir el compte Google+. Log Out /  Canvia )

Twitter picture

Esteu comentant fent servir el compte Twitter. Log Out /  Canvia )

Facebook photo

Esteu comentant fent servir el compte Facebook. Log Out /  Canvia )

S'està connectant a %s